The U.S. Food and Drug Administration granted clearance for Akili’s EndeavorRx as a prescription treatment for children with attention deficit hyperactivity disorder (ADHD).
https://www.pharmalive.com/wp-content/uploads/2020/06/Endeavor_Soup-Business-Wire-6-15-20.jpg222480Business Wirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBusiness Wire2020-06-15 15:31:582020-06-20 18:58:42FDA Clears Akili’s EndeavorRx for Children with ADHD